Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Recent Advances in the Development of Bioartificial Pancreas Using 3D Bioprinting for the Treatment of Type 1 Diabetes: A Review

# ORCID logo , # , *
#
These authors have contributed equally to this work.
Version 1 : Received: 2 October 2023 / Approved: 2 October 2023 / Online: 2 October 2023 (10:43:08 CEST)

A peer-reviewed article of this Preprint also exists.

Ghosh A, Sanyal A, Mallick A. Recent advances in the development of bioartificial pancreas using 3D bioprinting for the treatment of type 1 diabetes: a review. Explor Med. 2023;4:886–922.https://doi.org/10.37349/emed.2023.00184 Ghosh A, Sanyal A, Mallick A. Recent advances in the development of bioartificial pancreas using 3D bioprinting for the treatment of type 1 diabetes: a review. Explor Med. 2023;4:886–922.https://doi.org/10.37349/emed.2023.00184

Abstract

Type 1 diabetes is a chronic condition that results from the destruction of insulin-producing β-cells in the pancreas. Current treatments for type 1 diabetes, such as insulin therapy and pancreatic islet transplantation, have several limitations and, hence not quite effective in the long run. As current therapy methods fail to slow disease development, novel strategies such as the development of a bioartificial pancreas are being seriously considered. Over the last decade, research has focused on tissue engineering, which aids in the design of biological alternatives for the repair and replacement of non-functional or damaged organs. Three dimensional (3D) bioprinting technology which employs 3D printing technology to generate 3D tissue-like structures from biomaterials and cells, offers a promising solution for the treatment of type 1 diabetes by providing the ability to generate functional endocrine pancreatic tissue. Bioprinted structures are therefore an important aspect of tissue engineering because they have been found to replicate the native extracellular matrix, promoting cell survival and proliferation. In this review, we extensively discussed about bioprinting endocrine pancreas for the treatment of type 1 diabetes particularly focussing on the choice of cells, biomaterials, growth factors, and essential considerations. Additionally, the key challenges and perspectives towards recapitulation of the pancreatic function of the pancreatic organ engineering technologies have also been discussed.

Keywords

Biomaterials; 3D bioprinting; pancreas; islets; type 1 diabetes; biofabrication

Subject

Biology and Life Sciences, Endocrinology and Metabolism

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.